Andrea Valeria Arrossi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Andrea Valeria Arrossi has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Atul C. Mehta
Integrated Hospital Care Institute, Department of Pulmonary Medicine, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
3 shared publications - Ruchi Yadav
Cleveland Clinic, 9500 Euclid Avenue, Cleveland, Ohio, 44195-5243, UNITED STATES
3 shared publications - Humberto Choi
Respiratory Institute
2 shared publications - Subha Ghosh
Imaging Institute, Cleveland Clinic, Cleveland, Ohio, USA
2 shared publications - Tanmay S. Panchabhai
Norton Thoracic Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ, USA
2 shared publications - Adriano Roberto Tonelli
Department of Pulmonary Medicine, Integrated Hospital Care Institute, Cleveland Clinic, OH
1 shared publication
Latest Publications
- Open Access
- 1 December 2023
- Published by Oxford University Press (OUP) in Oxford Medical Case Reports
- Vol. 2023 (12) , omad091
Panacinar emphysema complicating idiopathic pulmonary hemosiderosis: a case report
Idiopathic pulmonary hemosiderosis (IPH) is a rare entity with no known underlying etiology. It can be complicated by lung fibrosis. Emphysema is rarely reported as a consequence of IPH. We present a case of a 30-year-old female who presented with recurrent hemoptysis and shortness of breath. Radiographs revealed advanced emphysematous changes of the lower lobes. The diagnosis of IPH was established with an open lung biopsy. She was treated with systemic steroids, underwent bullectomy and was subsequently maintained on inhaled steroids.
- 1 December 2023
- Published by Oxford University Press (OUP) in Oxford Medical Case Reports
- Vol. 2023 (12) , omad091
Open AccessPanacinar emphysema complicating idiopathic pulmonary hemosiderosis: a case report
Idiopathic pulmonary hemosiderosis (IPH) is a rare entity with no known underlying etiology. It can be complicated by lung fibrosis. Emphysema is rarely reported as a consequence of IPH. We present a case of a 30-year-old female who presented with recurrent hemoptysis and shortness of breath. Radiographs revealed advanced emphysematous changes of the lower lobes. The diagnosis of IPH was established with an open lung biopsy. She was treated with systemic steroids, underwent bullectomy and was subsequently maintained on inhaled steroids.
- 31 May 2023
- Published by Wiley in Histopathology
- Vol. 83 (3) , 487-489
All that glitters isn't gold: an unusual case of Pneumocystis jirovecii pneumonia
- 31 May 2023
- Published by Wiley in Histopathology
- Vol. 83 (3) , 487-489
All that glitters isn't gold: an unusual case of Pneumocystis jirovecii pneumonia
- 27 April 2023
- Published by Wolters Kluwer Health in Advances in Anatomic Pathology
- Vol. 30 (4) , 253-258
Pericardial Mesotheliomas
Primary pericardial mesothelioma (PM) is a rare tumor arising from the mesothelial cells of the pericardium. It has an incidence of <0.05% and comprises <2% of all mesotheliomas; however, it is the most common primary malignancy of the pericardium. PM should be distinguished from secondary involvement by the spread of pleural mesothelioma or metastases, which are more common. Although data are controversial, the association between asbestos exposure and PM is less documented than that with other mesotheliomas. Late clinical presentation is common. Symptoms may be nonspecific but are usually related to pericardial constriction or cardiac tamponade, and diagnosis can be challenging usually requiring multiple imaging modalities. Echocardiography, computed tomography, and cardiac magnetic resonance demonstrate heterogeneously enhancing thickened pericardium, usually encasing the heart, with findings of constrictive physiology. Tissue sampling is essential for diagnosis. Histologically, similar to mesotheliomas elsewhere in the body, PM is classified as epithelioid, sarcomatoid, or biphasic, with the biphasic type being the most common. Combined with morphologic assessment, the use of immunohistochemistry and other ancillary studies is helpful for distinguishing mesotheliomas from benign proliferative processes and other neoplastic processes. The prognosis of PM is poor with about 22% 1-year survival. Unfortunately, the rarity of PM poses limitations for comprehensive and prospective studies to gain further insight into the pathobiology, diagnosis, and treatment of PM.
- 27 April 2023
- Published by Wolters Kluwer Health in Advances in Anatomic Pathology
- Vol. 30 (4) , 253-258
Pericardial Mesotheliomas
Primary pericardial mesothelioma (PM) is a rare tumor arising from the mesothelial cells of the pericardium. It has an incidence of <0.05% and comprises <2% of all mesotheliomas; however, it is the most common primary malignancy of the pericardium. PM should be distinguished from secondary involvement by the spread of pleural mesothelioma or metastases, which are more common. Although data are controversial, the association between asbestos exposure and PM is less documented than that with other mesotheliomas. Late clinical presentation is common. Symptoms may be nonspecific but are usually related to pericardial constriction or cardiac tamponade, and diagnosis can be challenging usually requiring multiple imaging modalities. Echocardiography, computed tomography, and cardiac magnetic resonance demonstrate heterogeneously enhancing thickened pericardium, usually encasing the heart, with findings of constrictive physiology. Tissue sampling is essential for diagnosis. Histologically, similar to mesotheliomas elsewhere in the body, PM is classified as epithelioid, sarcomatoid, or biphasic, with the biphasic type being the most common. Combined with morphologic assessment, the use of immunohistochemistry and other ancillary studies is helpful for distinguishing mesotheliomas from benign proliferative processes and other neoplastic processes. The prognosis of PM is poor with about 22% 1-year survival. Unfortunately, the rarity of PM poses limitations for comprehensive and prospective studies to gain further insight into the pathobiology, diagnosis, and treatment of PM.
- Open Access
- 24 June 2022
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 12, 881553
Thymomas With Intravascular and Intracardiac Growth
Thymomas are derived from the epithelial component of the thymus and constitute the most common tumor of the anterior mediastinum. These neoplasms are considered malignant for their potential for invasion and metastases. Several histopathologic subclassification schemes have been proposed over the years, however, correlation of histotypes with prognosis remains controversial. In contrast, studies invariably have shown that staging and resection status correlate with oncologic behavior and disease outcomes. In this regard, several staging systems have been presented, though transcapsular invasion and degree of involvement of adjacent anatomic structures are common denominators of all schemes. Involvement of the great vessels and heart most commonly results from direct invasion, which may lead to unusual clinical presentations such as superior vena cava syndrome. Moreover, intravascular and intracardiac growth with or without direct mural invasion rarely occurs. We provide an overview of thymomas with intravascular and intracardiac involvement.
- 24 June 2022
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 12, 881553
Open AccessThymomas With Intravascular and Intracardiac Growth
Thymomas are derived from the epithelial component of the thymus and constitute the most common tumor of the anterior mediastinum. These neoplasms are considered malignant for their potential for invasion and metastases. Several histopathologic subclassification schemes have been proposed over the years, however, correlation of histotypes with prognosis remains controversial. In contrast, studies invariably have shown that staging and resection status correlate with oncologic behavior and disease outcomes. In this regard, several staging systems have been presented, though transcapsular invasion and degree of involvement of adjacent anatomic structures are common denominators of all schemes. Involvement of the great vessels and heart most commonly results from direct invasion, which may lead to unusual clinical presentations such as superior vena cava syndrome. Moreover, intravascular and intracardiac growth with or without direct mural invasion rarely occurs. We provide an overview of thymomas with intravascular and intracardiac involvement.
- 1 June 2021
- Published by Radiological Society of North America (RSNA) in Radiology: Cardiothoracic Imaging
- Vol. 3 (3) , e200586
Emphysema with Placental Transmogrification and Lipomatous Change
- 1 June 2021
- Published by Radiological Society of North America (RSNA) in Radiology: Cardiothoracic Imaging
- Vol. 3 (3) , e200586
Emphysema with Placental Transmogrification and Lipomatous Change
- Open Access
- 1 February 2021
- Published by Oxford University Press (OUP) in Oxford Medical Case Reports
- Vol. 2021 (2) , 50-52
A Unique Case of Combined Nodular and Tracheobronchial Amyloidosis
Amyloidosis is a heterogeneous group of diseases characterized by the extracellular deposition of misfolded proteins that can affect either systemically or locally confined to one system. Pulmonary amyloidosis is rare and can be classified into three forms according to the anatomic site of involvement: nodular pulmonary amyloidosis, tracheobronchial amyloidosis and diffuse alveolar-septal amyloidosis. The former two usually represent localized amyloid disease and the latter represents systemic disease. Typically lung parenchymal and tracheobronchial amyloidosis do not present together in localized forms of pulmonary amyloidosis. Here we report a unique case of localized pulmonary immunoglobulin light-chain amyloidosis, manifested as both parenchymal nodules and tracheobronchial amyloid deposition.
- 1 February 2021
- Published by Oxford University Press (OUP) in Oxford Medical Case Reports
- Vol. 2021 (2) , 50-52
Open AccessA Unique Case of Combined Nodular and Tracheobronchial Amyloidosis
Amyloidosis is a heterogeneous group of diseases characterized by the extracellular deposition of misfolded proteins that can affect either systemically or locally confined to one system. Pulmonary amyloidosis is rare and can be classified into three forms according to the anatomic site of involvement: nodular pulmonary amyloidosis, tracheobronchial amyloidosis and diffuse alveolar-septal amyloidosis. The former two usually represent localized amyloid disease and the latter represents systemic disease. Typically lung parenchymal and tracheobronchial amyloidosis do not present together in localized forms of pulmonary amyloidosis. Here we report a unique case of localized pulmonary immunoglobulin light-chain amyloidosis, manifested as both parenchymal nodules and tracheobronchial amyloid deposition.
- 23 September 2020
- Published by Cleveland Clinic Journal of Medicine in Cleveland Clinic Journal of Medicine
The pulmonary pathology of COVID-19
A growing number of international postmortem studies identify acute and organizing diffuse alveolar damage (DAD) as the main pathologic feature of lung injury in patients with COVID-19. Other forms of acute lung injury, including organizing pneumonia, and acute fibrinous and organizing pneumonia are seen. Acute neutrophilic infiltrates have been observed, most frequently as the manifestation of a superimposed bacterial pneumonia. SARS-CoV-2 has been detected in type I and type II pneumocytes and bronchial epithelial cells using electron microscopy, immunohistochemistry, and in situ hybridization, and likewise, viral transcripts were localized with RNA probes in pneumocytes. However, the presence of true viral cytopathic effect seen with light microscopy remains to be defined. Interestingly, vascular changes are frequently observed in association with DAD, which include severe endothelial injury/endothelialitis, hemorrhage, and thrombotic and microangiopathic vasculopathy. Since similar vascular changes also occur in cases of DAD independent of the etiology, whether the vascular pathology in COVID lungs has unique features and represents a separate pathologic process is under investigation.
- 23 September 2020
- Published by Cleveland Clinic Journal of Medicine in Cleveland Clinic Journal of Medicine
The pulmonary pathology of COVID-19
A growing number of international postmortem studies identify acute and organizing diffuse alveolar damage (DAD) as the main pathologic feature of lung injury in patients with COVID-19. Other forms of acute lung injury, including organizing pneumonia, and acute fibrinous and organizing pneumonia are seen. Acute neutrophilic infiltrates have been observed, most frequently as the manifestation of a superimposed bacterial pneumonia. SARS-CoV-2 has been detected in type I and type II pneumocytes and bronchial epithelial cells using electron microscopy, immunohistochemistry, and in situ hybridization, and likewise, viral transcripts were localized with RNA probes in pneumocytes. However, the presence of true viral cytopathic effect seen with light microscopy remains to be defined. Interestingly, vascular changes are frequently observed in association with DAD, which include severe endothelial injury/endothelialitis, hemorrhage, and thrombotic and microangiopathic vasculopathy. Since similar vascular changes also occur in cases of DAD independent of the etiology, whether the vascular pathology in COVID lungs has unique features and represents a separate pathologic process is under investigation.
- Open Access
- 1 May 2020
- Published by Oxford University Press (OUP)
- p. A1840
Respiratory Bronchiolitis Due to Volcano® Vaporizer Use
- 1 May 2020
- Published by Oxford University Press (OUP)
- p. A1840
Open AccessRespiratory Bronchiolitis Due to Volcano® Vaporizer Use
- Open Access
- 1 January 2020
- Published by Elsevier in Respiratory Medicine Case Reports
- Vol. 31, 101179
Vaping-related pulmonary granulomatous disease
- 1 January 2020
- Published by Elsevier in Respiratory Medicine Case Reports
- Vol. 31, 101179
Open AccessVaping-related pulmonary granulomatous disease
- 1 September 2019
- Published by Elsevier in Clinics in Chest Medicine
- Vol. 40 (3) , 667-677
Pulmonary Pathology in Rheumatic Disease
- 1 September 2019
- Published by Elsevier in Clinics in Chest Medicine
- Vol. 40 (3) , 667-677
Pulmonary Pathology in Rheumatic Disease